Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 13;12:1004700. doi: 10.3389/fonc.2022.1004700

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Ma, Zhu, Cheng, Chen, Shu and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

FGL2 plays an immunosuppressive function in the glioma microenvironment.1, FGL2 secreted by tumor cells binds to FCGR2B on immature DC cells and inhibits DC cell maturation and thus T cell proliferation by blocking the TAK1/NF-κB, p38, and JAK2/STAT5/STAT1 pathways.2, FGL2 inhibits the immune activators IL-2 and IFN-γ production, promotes immunosuppressive factors IL-4 and IL-10, increases Treg, and inhibits T-cell activation.3, FGL2 induces macrophages toward the M2 phenotype and produces CXCL7 in M2 cells via the FCGR2B/Syk/PI3K/AKT/HIF1α pathway, and CXCL7, in turn, acts on GSC to promote glioma cell stemness maintenance.